Rituximab addition to chemotherapy in real world patients with chronic lymphocytic leukemia: effective in first line but indication of lack of efficacy in subsequent lines of therapy-Reference-Cited by-同舟云学术

Rituximab addition to chemotherapy in real world patients with chronic lymphocytic leukemia: effective in first line but indication of lack of efficacy in subsequent lines of therapy

Published:2018-04-04 Issue:11 Volume:59 Page:2757-2761
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

van der Straten Lina¹^ORCID,Dinmohamed Avinash G.²³⁴^ORCID,Westerweel Peter E.¹,Langerak Anton W.⁵,Riedl Jurgen⁶,Doorduijn Jeanette K.⁴,Kater Arnon P.⁷,Levin Mark-David¹

Affiliation:

1. Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands;

2. Department of Research, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands;

3. Department of Public Health, Erasmus University Medical Centre, Rotterdam, The Netherlands;

4. Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands;

5. Department of Immunology, Erasmus University Medical Centre, Rotterdam, The Netherlands;

6. Department of Clinical Chemistry, Result laboratories, Albert Schweitzer Hospital, Dordrecht, The Netherland;

7. Department of Hematology, Academic Medical Centre, Amsterdam, the Netherlands

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2018.1452215

Reference11 articles.

1. Improved survival outcomes with the addition of rituximab to initial therapy for chronic lymphocytic leukemia: a comparative effectiveness analysis in the province of British Columbia, Canada

2. Reevaluating Eligibility Criteria — Balancing Patient Protection and Participation in Oncology Trials

3. Low-dose fludarabine with or without darbepoetin alfa in patients with chronic lymphocytic leukemia and comorbidity: primary results of the CLL9 trial of the German CLL Study Group

4. Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

5. Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG)

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Possible hampered effectiveness of second-line treatment with rituximab-containing chemotherapy without signs of rituximab resistance: a population-based study among patients with chronic lymphocytic leukemia;Annals of Hematology;2020-03-19